![Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire](https://mms.businesswire.com/media/20190401005264/en/396178/22/puma_logo_JPEG.jpg)
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
![Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America](https://www.pint-pharma.com/images/st_metanic/blog/blog-2.png)
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
![Puma Biotechnology, Inc. 2021 Q2 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha Puma Biotechnology, Inc. 2021 Q2 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha](https://static2.seekingalpha.com/uploads/sa_presentations/324/73324/slides/8.jpg?1628520905)
Puma Biotechnology, Inc. 2021 Q2 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
![Puma Biotechnology, Inc. Analytics - Traffic, Statistics and Competitor tracking | WatchMyCompetitor Puma Biotechnology, Inc. Analytics - Traffic, Statistics and Competitor tracking | WatchMyCompetitor](https://www.watchmycompetitor.com/Content/img/publicpages/id-4479-date-2020-08-03.png)
Puma Biotechnology, Inc. Analytics - Traffic, Statistics and Competitor tracking | WatchMyCompetitor
![Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer | Business Wire Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer | Business Wire](https://mms.businesswire.com/media/20171212006311/en/629578/5/3143937_120917_DSI_Logo_Portrait_4c_CMYK_Original_JPG.jpg)
Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer | Business Wire
![Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire](https://mms.businesswire.com/media/20190401005264/en/396178/5/puma_logo_JPEG.jpg)